Natixis Glaukos Corp Transaction History

Natixis

$17.6 Billion
Q3 2024

A detailed history of Natixis transactions in Glaukos Corp stock. As of the latest transaction made, Natixis holds 1 shares of GKOS stock, worth $156. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 13,802 99.99%

Holding current value

$156

Previous $1.63 Million 100.0%

% of portfolio

0.0%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$113.62 - $135.39 $1.57 Million - $1.87 Million	-13,801 Reduced 99.99%	1 $0
Q2 2024 Aug 13, 2024	BUY	$89.48 - $118.35 $652,040 - $862,416	7,287 Added 111.85%	13,802 $1.63 Million
Q1 2024 May 13, 2024	BUY	$76.4 - $96.33 $497,746 - $627,589	6,515 New	6,515 $614,000
Q3 2023 Nov 14, 2023	BUY	$69.23 - $79.09 $4.32 Million - $4.94 Million	62,469 New	62,469 $4.7 Million
Q3 2022 Nov 14, 2022	BUY	$46.84 - $58.49 $363,010 - $453,297	7,750 New	7,750 $413,000
Q1 2022 May 13, 2022	SELL	$44.33 - $57.82 $1.15 Million - $1.5 Million	-26,000 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$40.27 - $56.99 $7.47 Million - $10.6 Million	-185,400 Reduced 87.7%	26,000 $1.16 Million
Q2 2021 Aug 13, 2021	SELL	$73.06 - $97.7 $4.38 Million - $5.86 Million	-60,000 Reduced 22.11%	211,400 $17.9 Million
Q1 2021 May 14, 2021	SELL	$70.43 - $97.42 $3.06 Million - $4.23 Million	-43,400 Reduced 13.79%	271,400 $22.8 Million
Q4 2020 Feb 12, 2021	SELL	$48.9 - $75.26 $16.9 Million - $26 Million	-345,400 Reduced 52.32%	314,800 $23.7 Million
Q3 2020 Nov 12, 2020	BUY	$37.23 - $50.97 $24.6 Million - $33.7 Million	660,200 New	660,200 $32.7 Million

Others Institutions Holding GKOS

# of Institutions

342

Shares Held

46.8M

Call Options Held

132K

Put Options Held

188K

View Full List

About GLAUKOS Corp

Ticker GKOS
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 47,596,900
Market Cap $7.45B
Description
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-...

More about GKOS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

News

Stay updated on Natixis with notifications on news.

Account